Long-Acting Injectable Program Implementation Insights From Genoa Healthcare® Pharmacy

Listen

0:00 / 0:00

This educational resource was sponsored by Johnson & Johnson.

Part 2 of this educational resource provides insights for institutions seeking to implement a pharmacist-led long-acting injectable administration program for schizophrenia.

Articles in this issue

10 months ago

Article

Optimizing Long-Acting Injectable Administration for Patients Living With Schizophrenia

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Long-Acting Injectable Program Implementation Insights From Genoa Healthcare® Pharmacy

Articles in this issue

Trending on AJMC

Medicaid MFN Pricing Could Save $8.6 Billion

CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks

Active US Drug Shortages Rise for Third Straight Quarter

Access Barriers, Not Science, Slow Retina Care: Paul Hahn, MD

Early-Onset CKD Mortality Declines Globally as Incidence Continues to Rise